ClinicalTrials.gg
Not yet recruitingNCT07449780Updated Mar 4, 2026

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

A Phase 3 interventional study of AK104(SC) and AK104(IV) in Gastric / Gastroesophageal Junction Adenocarcinoma, sponsored by Akeso. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

02

Conditions studied

  • Gastric / Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).
  2. Unresectable locally advanced or adenocarcinoma of the stomach or gastroesophageal junction (GEJ).
  3. Participants have not received prior systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
  4. Adequate organ and bone marrow function.
  5. (ECOG) performance status of 0 or 1 at enrollment.
  6. by 1.1.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of systemic non-specific immunomodulatory therapy (e.g., interleukins, interferons, thymic peptides, etc.) within 2 weeks prior to the first dose.Receipt of Chinese herbal medicines or Chinese patent medicines with anti-tumor indications within 2 weeks prior to the first dose.
  2. Deep venous thrombosis within 3 months before first treatment.
  3. Uncontrolled arterial hypertension.
  4. Bleeding events within the last 1 months.
  5. Prior treatment with .
  6. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
422 participants (estimated)

Study arms

  • Experimental
    AK104(SC)+XELOX

    AK104 SC plus XELOX

    Drug: AK104(SC) · Drug: Capecitabine · Drug: Oxaliplatin injection

  • Active comparator
    AK104(IV)+XELOX

    AK104 IV plus XELOX

    Drug: AK104(IV) · Drug: Capecitabine · Drug: Oxaliplatin injection

Interventions

06

What researchers measure

Primary outcomes

  1. Measured serum trough concentration (Ctrough) of AK104 after the first administration (i.e., prior to dosing in Cycle 2).

    Measured serum trough concentration (Ctrough) of AK104 after the first administration (i.e., prior to dosing in Cycle 2).

    Time frame: up to 4 weeks

  2. Measured area under the concentration-time curve from 0 to 21 days of AK104 after the first administration.

    Measured area under the concentration-time curve from 0 to 21 days of AK104 after the first administration.

    Time frame: up to 4 weeks

Secondary outcomes

  1. Objective Response Rate (ORR) per RECIST 1.1

    Assessed by investigators

    Time frame: up to 24 months

  2. Disease Control Rate (DCR) per RECIST 1.1

    Assessed by investigators

    Time frame: Up to 24 months

  3. Progression-free survival (PFS) assessed by investigator per RECIST v1.1

    PFS is defined as the time from randomization till the first documented disease progression (Per RECIST v1.1 assessed by the investigator) or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months

  4. Duration of Response (DOR) assessed by investigator per RECIST v1.1

    DOR means time measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

    Time frame: Up to 24 months

  5. Time to Response (TTR) assessed by investigator per RECIST v1.1

    TTR refers to Time to Response.

    Time frame: Up to 24 months

  6. Overall Survival

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to 24 months

  7. Number of participants with adverse event (AE)

    The number of participants experiencing an Adverse Event (AE) and the severity of AEs will be assessed. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

    Time frame: Up to 27 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Nov 2027, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartEst.
Mar 31, 2026
Primary completionEst.
Nov 17, 2027
CompletionEst.
Feb 15, 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07449780
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 31, 2026 (estimated)
Primary completion
Nov 17, 2027 (estimated)
Completion
Feb 15, 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Ting Liu
Contact
clinicaltrials@akesobio.com
+86 (0760) 8987 3999
Yanqiao Zhang
principal investigator · The Second Affiliated Hospital of Harbin Medical University
Tao Zhang
principal investigator · UNIVERSITY OF SCIENCE AND TECHNOLOGY UNION HOSPITAL TONG JI MEDICAL COLLEGE HUA ZHONG

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion